Importantly, the HSPG2 treatment did not increase the leukaemia cell‐supporting ability of CR EPCs, which specifically manifested as no significant increase in cell proliferation ability (Figure 6B,C), no significant decrease in cell apoptosis (Figure 6D) and no significant changes in the CFU‐L formation ability (Figure 6E,F). Here, HSPG2 is linked to leukemia.